Treatments in Endocrinology

, Volume 1, Issue 2, pp 127–129 | Cite as

Spotlight on Estradiol and Norgestimate as Hormone Replacement Therapy in Postmenopausal Women

Adis Spotlight

Abstract

The focus of this review is hormone replacement therapy (HRT) with continuous administration of micronized, oral 17β-estradiol 1 mg/day (herein referred to as continuous estradiol) plus micronized, oral norgestimate 90 μg/day administered for 3 days then withdrawn for 3 days in a 6-day repeating sequence (herein referred to as intermittent norgestimate).

According to data from randomized, comparative trials of 1 year’s duration, continuous estradiol 1 mg/day plus intermittent norgestimate 90 μg/day relieves climacteric symptoms (vasomotor symptoms and vulvovaginal atrophy) in postmenopausal women. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 μg/day appeared as effective as estradiol 1 mg/day alone or continuous estradiol 2 mg/day plus continuous norethisterone acetate 1 mg/day in the treatment of postmenopausal women with vasomotor symptoms. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 μg/day was as effective as continuous estradiol 1 mg/day in causing the maturation of vaginal epithelial cells.

In a randomized, double-blind study, bone mineral density (BMD) increased to a significantly greater extent and the rate of bone turnover was slower in postmenopausal women treated with continuous oral estradiol 1 mg/day plus intermittent norgestimate 90 μg/day than in placebo-treated patients.

Two randomized, double-blind studies indicated that the addition of norgestimate 90 μg/day to continuous estradiol 1 mg/day did not attenuate the beneficial effects of estradiol on lipid parameters. Continuous estradiol 1 mg/day plus intermittent norgestimate 90 μg/day was associated with increases in mean serum high density lipoprotein (HDL)-cholesterol levels and decreases in total cholesterol, low density lipoprotein (LDL)-cholesterol and lipoprotein (a) levels, compared with baseline. There was no statistically significant increase in triglyceride levels.

In comparative trials, continuous oral estradiol 1 mg/day plus intermittent oral norgestimate 90 μg/day was well tolerated. Headache, breast pain or discomfort, abdominal pain or discomfort, uterine bleeding, dysmenorrhea, edema, nausea and depression were the most commonly reported adverse events. Continuous estradiol 1 mg/day plus intermittent oral norgestimate 90 μg/day was associated with a favorable uterine bleeding profile that improved over time. In a randomized trial, 80% of women were free from bleeding (irrespective of spotting) during month 12 of treatment. Norgestimate 90 μg/day was effective in protecting postmenopausal women against induction of endometrial hyperplasia by continuous estradiol 1 mg/day.

In conclusion, data from a limited number of randomized studies indicate that HRT with continuous estradiol 1 mg/day plus intermittent norgestimate 90 μg/day is effective in relieving climacteric symptoms, increasing BMD and slowing the rate of bone turnover in postmenopausal women. This HRT regimen is well tolerated and is associated with a similar incidence of adverse events to that reported in recipients of continuous estradiol 1 mg/day. The norgestimate component of the regimen provides good endometrial protection and is associated with a favorable bleeding profile. Long-term studies investigating the associated risk of breast cancer and thromboembolic events in recipients of continuous estradiol plus intermittent norgestimate are needed. In the meantime, continuous oral estradiol plus intermittent oral norgestimate can be regarded as an effective new option for HRT in postmenopausal women.

Keywords

Postmenopausal Woman Estradiol Hormone Replacement Therapy Endometrial Hyperplasia Vasomotor Symptom 

Notes

Acknowledgements

The full text article in Drugs and Aging 2001; 18 (11): 863–885 was reviewed by: D. Felsenberg, Osteoporosis Research Group, Free University of Berlin, Berlin, Germany; T.C. Hillard, Department of Obstetrics & Gynaecology, Poole Hospital NHS Trust, Poole, England; R.M. Richart, Columbia University College of Physicians & Surgeons, New York, New York, USA; O. Ylikorkala, Department of Obstetrics & Gynaecology, Helsinki University Central Hospital, Helsinki, Finland; H.Z. Zacur, John Hopkins Medical Hospital, Baltimore, Maryland, USA.

References

  1. 1.
    Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil 1996;41: 16–21Google Scholar
  2. 2.
    Casper RF. Estrogen with interrupted progestin HRT: a review of experimental and clinical trials. Maturitas 2000; 34: 97–108PubMedCrossRefGoogle Scholar
  3. 3.
    Rozenberg S. Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2001; 94: 86–91PubMedCrossRefGoogle Scholar
  4. 4.
    Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17 β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22(5): 622–36PubMedCrossRefGoogle Scholar
  5. 5.
    Lobo RA, Zacur HZ, Caubel P, et al. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17 β-estradiol on lipid and lipoprotein profiles. Am J Obstet Gynecol 2000; 182: 41–9PubMedCrossRefGoogle Scholar
  6. 6.
    Prescribing information: Ortho-Prefest® (estradiol/norgestimate) tablets. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc., 1999Google Scholar
  7. 7.
    Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–9PubMedCrossRefGoogle Scholar
  8. 8.
    Corson SL, Richart RM, Caubel P, et al. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17 β-estradiol and norgestimate on endometrial histology. Int J Fertil 1999 Nov–Dec; 44: 279–85Google Scholar
  9. 9.
    Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil 1999; 44: 286–96Google Scholar
  10. 10.
    Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynecol Obstet 2001 Mar; 72: 235–43CrossRefGoogle Scholar
  11. 11.
    Felsenberg D, van der Ouweland F, Friedman MD. Ortho-Prefest® for the prevention of bone loss in postmenopausal women [abstract no. 107]. North American Menopause Society 12th Annual Meeting; 2001 Oct 4–6; New OrleansGoogle Scholar

Copyright information

© Adis Data Information BV 2002

Authors and Affiliations

  1. 1.Adis International Inc.LanghorneUSA

Personalised recommendations